Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) — Working Capital to Net Assets Ratio
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) has a Working Capital to Net Assets ratio of 60.5% as of September 2025. Working capital of CN¥1.65 Billion (current assets of CN¥1.77 Billion minus current liabilities of CN¥119.95 Million) is measured against net assets of CN¥2.73 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 300357 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Working Capital to Net Assets (2009–2024)
This chart shows how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 16 annual periods from 2009 to 2024. As of September 2025, the ratio stands at 60.5%, reflecting working capital of CN¥1.65 Billion against net assets of CN¥2.73 Billion CNY. See 300357 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (2009–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd from 2009 to 2024, covering 16 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 300357 market cap overview.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 59.7% | CN¥1.47 Billion | CN¥2.46 Billion | CN¥1.65 Billion | CN¥182.58 Million | ▼ -0.7 pp |
| 2023 | 60.5% | CN¥1.39 Billion | CN¥2.30 Billion | CN¥1.57 Billion | CN¥177.04 Million | ▼ -7.3 pp |
| 2022 | 67.8% | CN¥1.37 Billion | CN¥2.03 Billion | CN¥1.48 Billion | CN¥102.75 Million | ▼ -0.9 pp |
| 2021 | 68.7% | CN¥1.23 Billion | CN¥1.80 Billion | CN¥1.34 Billion | CN¥108.00 Million | ▼ -4.3 pp |
| 2020 | 73.0% | CN¥1.12 Billion | CN¥1.53 Billion | CN¥1.17 Billion | CN¥55.42 Million | ▼ -0.2 pp |
| 2019 | 73.2% | CN¥989.97 Million | CN¥1.35 Billion | CN¥1.05 Billion | CN¥60.03 Million | ▲ +0.5 pp |
| 2018 | 72.7% | CN¥724.04 Million | CN¥995.42 Million | CN¥781.66 Million | CN¥57.62 Million | ▼ -3.9 pp |
| 2017 | 76.7% | CN¥614.30 Million | CN¥801.26 Million | CN¥656.50 Million | CN¥42.20 Million | ▼ 0.0 pp |
| 2016 | 76.7% | CN¥502.75 Million | CN¥655.58 Million | CN¥539.21 Million | CN¥36.46 Million | ▼ -2.2 pp |
| 2015 | 78.9% | CN¥459.65 Million | CN¥582.91 Million | CN¥484.28 Million | CN¥24.63 Million | ▼ -5.0 pp |
| 2014 | 83.9% | CN¥430.72 Million | CN¥513.55 Million | CN¥446.92 Million | CN¥16.20 Million | ▲ +11.2 pp |
| 2013 | 72.7% | CN¥183.05 Million | CN¥251.92 Million | CN¥195.08 Million | CN¥12.04 Million | ▲ +2.7 pp |
| 2012 | 70.0% | CN¥126.89 Million | CN¥181.38 Million | CN¥134.85 Million | CN¥7.96 Million | ▲ +8.8 pp |
| 2011 | 61.2% | CN¥78.06 Million | CN¥127.61 Million | CN¥94.99 Million | CN¥16.92 Million | ▲ +15.4 pp |
| 2010 | 45.8% | CN¥41.41 Million | CN¥90.44 Million | CN¥57.95 Million | CN¥16.54 Million | ▼ -17.1 pp |
| 2009 | 62.9% | CN¥70.40 Million | CN¥111.89 Million | CN¥75.47 Million | CN¥5.07 Million | — |